ITEM 1. | Security and Issuer. |
This Amendment No. 5 to Schedule 13D (this “Amendment No. 5”) is being filed by Exor N.V., a Dutch public limited liability company (naamloze vennootschap) (“Exor”), to amend the Schedule 13D filed by Exor S.p.A., a società per azioni organized under the laws of the Republic of Italy, as predecessor in interest to Exor, with the Securities and Exchange Commission (“SEC”) on October 22, 2014 (the “Original 13D”) as amended by Amendment No. 1 to Schedule 13D filed with the SEC on December 22, 2014 (“Amendment No. 1”), Amendment No. 2 to Schedule 13D filed with the SEC on December 15, 2016 (“Amendment No. 2”), Amendment No. 3 to Schedule 13D filed with the SEC on February 3, 2021 (“Amendment No. 3”) and Amendment No. 4 to Schedule 13D filed with the SEC on April 15, 2021 (“Amendment No. 4”, and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3 and this Amendment No. 5, “Schedule 13D”), and relates to the common shares, par value €0.01 per share, of Stellantis N.V., a Dutch public limited liability company (naamloze vennootschap) (the “Issuer”), the principal executive office of which is located at Taurusavenue 1, 2132 LS Hoofddorp, the Netherlands. Each capitalized term used and not defined herein shall have the meaning assigned to such term in the Original 13D, as amended. Except as otherwise provided herein, each Item of the Original 13D, as amended, remains unchanged.
This Amendment No. 5 is being filed to amend Item 2 and Item 5 as follows.
ITEM 2. | Identity and Background. |
Item 2 is hereby amended and partially restated by replacing the first paragraph with the following:
(a)-(c) This Schedule 13D is filed by Exor N.V. (“Exor” or the “Reporting Person”), a Dutch public limited liability company (naamloze vennootschap) and successor to Exor S.p.A. by virtue of a cross-border merger of Exor S.p.A. with and into Exor. Exor is an investment company, which focuses its business on long-term investments in global companies in diversified sectors, mainly in Europe and the United States. The address of Exor’s principal business and principal office is Gustav Mahlerplein 25, 1082 MS Amsterdam, the Netherlands. The name, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and citizenship of each executive officer and director of Exor, each person controlling Exor and each executive officer and director of any corporation or other person in control of Exor are set forth in Schedule A attached hereto.
ITEM 5. | Interest in Securities of the Issuer. |
Item 5 is hereby amended and partially restated by replacing paragraphs (a) through (c) with the following:
(a) Rows (11) and (13) of the cover page to this Amendment No. 5 are incorporated by reference herein.
(b) Rows (7) through (10) of the cover page to this Amendment No. 5 are hereby incorporated by reference herein.
Furthermore, the following persons listed in Item 2(a)(c) above beneficially own common shares of the Issuer:
| • | | Mr. John Elkann owns 1,047,609 common shares of record; |
| • | | Mr. Niccolò Camerana owns 5,499 common shares of record; and |
| • | | Mr. Alessandro Nasi owns 3,750 common shares of record. |
The persons listed in Schedule A hereto and named in Item 5 above have the sole voting power and sole dispositive power in respect of the entire number of shares indicated in this Item 5, above. There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.
(c) Neither the Reporting Person nor any persons listed in Schedule A have effected any transactions with respect to common shares of the Issuer during the past 60 days.
(d) There are no changes to the information set out in paragraph (d) of Item 5 of the Original 13D, as amended, and such information is incorporated by reference herein.
(e) There are no changes to the information set out in paragraph (e) of Item 5 of the Original 13D, as amended, and such information is incorporated by reference herein.
3